Head of U.S. clinical development program is David Richards, MD, who holds the title of senior VP-medical operations. Richards assumed that position last fall moving over from Glaxo Group Research, where he was a medical director. "The Pink Sheet" previously reported incorrectly that Peter Wise, MD, is head of the Glaxo, a medical director. "The Pink Sheet" previously reported incorrectly that Peter Wise, MD, is head of the Glaxo, Inc. clinical programs. Wise holds the title of senior VP-medical marketing and heads a research group that develops new uses for already marketed products as well as line extensions, dosage regimens, and new market niches.
You may also be interested in...
Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics.
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.
Limiting interactions to two-dimensional settings will hinder collaboration, innovation and the mentoring of younger employees, Merck & Co. CEO Kenneth Frazier says. Frazier, who will retire in June, is looking forward to returning to public service but says "politics with a capital P is not my thing."